Trial reportThe Journal of clinical endocrinology and metabolism2014
FSH suppression does not affect bone turnover in eugonadal men.
Trial report in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Extra-Gonadal and Non-Canonical Effects of FSH in Males.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Bones and Hormones: Interaction between Hormones of the Hypothalamus, Pituitary, Adipose Tissue and Bone.International journal of molecular sciences · 2023Review
- FSH and bone: Comparison between males with central versus primary hypogonadism.Frontiers in endocrinology · 2022Observational
- The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens.Endocrine reviews · 2021Review
- FSH Level and Changes in Bone Mass and Body Composition in Older Women and Men.The Journal of clinical endocrinology and metabolism · 2021Article
- First-in-class humanized FSH blocking antibody targets bone and fat.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies.Endocrinology · 2020Review
- FSH Beyond Fertility.Frontiers in endocrinology · 2019Review
- Modulation of Gonadotropins Activity by Antibodies.Frontiers in endocrinology · 2019Review
- Extragonadal FSHR Expression and Function-Is It Real?Frontiers in endocrinology · 2019Review
- The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Oncotarget · 2017Review
- Estrogens, the be-all and end-all of male hypogonadal bone loss?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- Sex steroid actions in male bone.Endocrine reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
contextIn vitro and animal studies have reported conflicting results regarding an independent role for FSH in the regulation of bone turnover.
objectiveOur objective was to test the hypothesis that suppressing serum FSH while holding serum gonadal steroid levels stable in the eugonadal range will affect biochemical markers of bone metabolism in healthy men. PARTICIPANTS, DESIGN, AND
settingEugonadal men aged 20 to 50 years participated in this randomized controlled trial at a tertiary care academic teaching hospital.
interventionsParticipants received monthly GnRH analog injections to suppress FSH secretion plus daily topical testosterone gel in prespecified doses (intervention group). Controls received matching placebos (control group). Subjects in the intervention group were individually matched with subjects in the control group to ensure that the mean testosterone and estradiol levels (measured every 4 weeks during the 16-week study period) in the 2 groups were similar.
main outcome measuresBiochemical markers of bone resorption (serum N-terminal telopeptide and C-terminal telopeptide), bone formation (serum osteocalcin), and FSH were measured at baseline and after 16 weeks of treatment.
resultsSerum FSH declined by 2% in the control group and by 60% in the intervention group (P < .0001 for the between-group difference). Despite the substantial suppression of serum FSH in the intervention group, serum N-terminal telopeptide, C-terminal telopeptide, and osteocalcin did not change in the intervention group, nor were any between-group differences observed.
conclusionWhen gonadal steroid levels are held constant, short-to midterm suppression of FSH does not affect bone turnover in men. FSH does not appear to be a significant regulator of bone metabolism in eugonadal men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.